Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results Of Spevatamig (PT886) In Combination With Chemotherapy In Frontline Treatment Of Metastatic PDAC At The 2026 ASCO Annual Meeting

(MENAFN - PR Newswire) SAN DIEGO, May 28, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, ...